Home World Politics Business Tech Health Science Climate Education

Balanced coverage of the week's biggest story. See every side. Know the truth.

By signing up for the Story of the Week newsletter you agree to our privacy policy.

Product

For You
Trending
Blindspot
Local
Compare
Brief
Trust

Topics

World
Politics
Business
Tech
Health
Science

Regions

Africa
Europe
Asia-Pacific
Americas
Middle East

Company

About
Contact
All topics
My Bias
Privacy
Terms & DMCA

KODAWIRE

KODAWIRE

© 2026 Kodawire

About Contact Privacy Terms Top

/

/

Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria

1 sources

Seeking Alpha (US)2h ago

Center

Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria

2026-09-22. The following slide deck was published by Celldex Therapeutics, Inc.

Spectrum

L 0%C 100%R 0%